Novel Therapeutic Targets for Management of Type-2 Diabetes Mellitus

A number of conventional therapeutic targets are available for treatment of Type 2 diabetes mellitus (T2DM) but due to development of resistance by using conventional drug as monotherapy, there is a need to identify novel therapeutic targets and/or use combination of conventional and novel drugs for diabetes therapy. In this review we have highlighted some of the novel approaches like inhibitors of (11β- Hydroxysteroid dehydrogenase type-1, Sodium-glucose linked cotransporter-2, Acyl-CoA Diacylglycerol Acyl Transferase-1, Glycogen phosphorylase-A, Pyruvate Dehydrogenase Kinase, Protein tyrosine phosphate 1B, Kappa kinase-B, Stearoyl-coA desaturase-1), antagonists of (Fatty acid binding proteins, Fibroblast growth factors-21 receptor, Glucagon receptor, Glucocorticoid receptors), Glucokinase and Sirtuin activators, Cannabinoid receptor blockers, Incretin-mimetics, agonists of (Adenosine monophosphate activated protein kinase, Augmenting GLP-1 secretion GPR40, GPR120, GPR 146 and TGR 5, GPCR 119, liver x receptors, Serotonin 2c receptor) and Rexinoids x receptor modulators developed for the treatment of diabetes.